Valuation: Eli Lilly and Company

Market Cap 1,224B 1,096B 1,008B 913B 1,707B 116,184B 1,739B 12,021B 4,826B 61,116B 4,592B 4,494B 192,738B P/E 2026 *
40.3x
P/E 2027 * 29.6x
Enterprise Value 1,251B 1,120B 1,031B 934B 1,745B 118,782B 1,778B 12,290B 4,934B 62,483B 4,695B 4,595B 197,048B EV / Sales 2026 *
13.7x
EV / Sales 2027 * 11.8x
Free-Float
99.84%
Yield 2026 *
0.5%
Yield 2027 * 0.56%
1 day+3.15%
1 week+10.92%
Current month+22.07%
1 month+22.07%
3 months+22.29%
6 months+51.13%
Current year+31.43%
1 week 1,260.34
Extreme 1260.34
1,449.68
1 month 1,131.21
Extreme 1131.21
1,449.68
Current year 850.51
Extreme 850.51
1,449.68
1 year 834.19
Extreme 834.19
1,449.68
3 years 547.61
Extreme 547.61
1,449.68
5 years 231.87
Extreme 231.87
1,449.68
10 years 64.18
Extreme 64.18
1,449.68
Manager TitleAgeSince
Chief Executive Officer 58 2016-12-31
Director of Finance/CFO 49 2024-09-08
Chief Tech/Sci/R&D Officer 52 -
Director TitleAgeSince
Director/Board Member 66 2004-12-31
Director/Board Member 70 2009-03-31
Director/Board Member 54 2011-12-11
Date Insider Type Main position Quantity % Market Cap. Importance
9/21/26 Free

Director

11 0.0000%
9/21/26 Free

Director

14 0.0000%
9/21/26 Free

Director

9 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
+2.86%+10.92%+67.26%+149.68% 1,224B
-0.69%+3.83%+44.88%+86.29% 662B
+1.28%+2.84%+28.73%+107.03% 514B
+0.42%+3.20%+54.15%+67.18% 388B
+2.34%+3.04%+73.48%+45.77% 361B
+1.12%+4.52%+35.30%+58.08% 302B
+6.96%+8.86%+11.27%+36.62% 271B
+1.25%+6.25%+59.83%+77.33% 249B
+3.10%+9.84%+44.71%+120.39% 205B
+2.21%+2.29%-17.54%-60.73% 172B
Average +2.24%+2.17%+40.21%+68.76% 434.88B
Weighted average by Cap. +2.05%+2.85%+48.09%+91.74%

Financials

2026 *2027 *
Net sales 91.49B 81.94B 75.37B 68.29B 128B 8,687B 130B 899B 361B 4,570B 343B 336B 14,411B 104B 93.57B 86.07B 77.99B 146B 9,920B 149B 1,026B 412B 5,218B 392B 384B 16,457B
Net income 30.68B 27.48B 25.28B 22.9B 42.81B 2,913B 43.61B 301B 121B 1,532B 115B 113B 4,833B 40.99B 36.71B 33.77B 30.6B 57.19B 3,892B 58.26B 403B 162B 2,047B 154B 151B 6,456B
Net Debt 27.37B 24.51B 22.54B 20.43B 38.18B 2,598B 38.9B 269B 108B 1,367B 103B 101B 4,310B 7.38B 6.61B 6.08B 5.51B 10.3B 701B 10.49B 72.54B 29.12B 369B 27.71B 27.12B 1,163B
Projected Income Statement - Annual - Eli Lilly and Company
Logo Eli Lilly and Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (74%): products for treating osteoporosis, diabetes, and growth problems; - oncology (14.4%); - immunology diseases (8.1%); - neurology (2.1%): primarily drugs used in treating depression and schizophrenia; - other (1.4%). Net sales are distributed geographically as follows: the United States (66.7%), Europe (17.7%), Japan (3.2%), China (3%) and other (9.4%).
Employees
50,000
Date Price Change Volume
26-10-30 US$1,413.70 +2.91% 3,418,044
26-10-29 US$1,373.70 +6.63% 4,373,521
26-10-28 US$1,288.30 +0.50% 2,061,427
26-10-27 US$1,281.91 +0.22% 1,849,712
26-10-26 US$1,279.14 +0.45% 2,106,876
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - Eli Lilly and Company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
1,373.70USD
Average target price
1,397.02USD
Spread / Average Target
+1.70%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Eli Lilly and Company